Marinomed Biotech AG Announces New R&D Collaboration with Aché Laboratórios

Marinomed Biotech AG, based in Korneuburg, Austria, has entered into a research and development partnership with Brazilian pharmaceutical company Aché Laboratórios Farmaceuticos S.A. This collaboration focuses on enhancing pharmaceutical compounds using Marinomed's Marinosolv technology, aimed at improving solubility and bioavailability of drugs.

The agreement grants Aché exclusive rights to utilize the Marinosolv technology in Latin America, targeting compounds for development into pharmaceutical products under the Aché brand. Marinomed expects to receive royalties following successful commercialization in the Latin American markets. The partnership also opens potential for future exploitation of these products outside Latin America, contingent on successful R&D outcomes.

Cornelia Siegl, Head of Solv4U at Marinomed, expressed enthusiasm about collaborating with an innovative partner like Aché, emphasizing the significance of addressing low drug solubility challenges in pharmaceutical development. Marinomed's CEO, Andreas Grassauer, highlighted the importance of this cooperation to Marinomed's expansion in Latin America, following a previous partnership in Shanghai.

From Aché's perspective, R&D Director Hatylas Azevedo anticipates this collaboration will enhance the therapeutic efficacy of treatments for prevalent diseases, leveraging Aché's robust experience in drug development and commercialization alongside Marinomed’s technological advancements.